The coronavirus (COVID-19) pandemic has affected all aspects of healthcare and the oncology and immuno-oncology communities may face unique challenges in regards to patient care. As immuno-oncology practitioners treat patients during the pandemic, it has also become apparent that the immunotherapy field may offer important insights into clinical practice, immune-related pathophysiology and other topics that may be useful to the broader healthcare community during this time of great need.
SITC is committed to providing the most current COVID-19 information and resources to its members and the oncology community at large. Resources will be updated on a regular basis throughout this rapidly evolving situation. Please continue to check back for the most current information.
SITC’s 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020), will include a Hot Topic Symposium co-chaired by Nina Bhardwaj, MD, PhD (Icahn School of Medicine, Mount Siani) and Jedd D. Wolchok, MD, PhD (Memorial Sloan Kettering Cancer Center) which focus on the impact of the COVID-19 pandemic on treatment of cancer patients with immunotherapy and on lessons from cancer immunotherapy and immunology that can be applied to the management of COVID-19 infection. Register today!
The Society for Immunotherapy of Cancer perspective on regulation of interleukin 6 signaling in COVID-19-related systemic inflammatory response
With an immunology-informed approach, the analysis reviews additional investigational therapies that could be explored as approaches to reduce the severe and damaging inflammatory response observed during COVID-19 infection.
Read More >>
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 To support clinicians working at the front lines of the COVID-19 pandemic, the Society for Immunotherapy of Cancer (SITC) is advocating for the pharmaceutical industry, health authorities and institutional IRBs to continue to work creatively and collaboratively to expand access to IL-6-targeting therapies for their potential use in critically-ill patients with COVID-19.
SITC Advocates for Scientific Journals to Grant Open Access for COVID-19 PublicationsThe Society for Immunotherapy of Cancer (SITC) has issued a call for all COVID-19-related research to be made open-access across all biomedical journals, to further facilitate exchange of information during the Coronavirus pandemic.
SITC has launched two new online communities to serve as discussion forums to facilitate global communication and rapidly disseminate critical information related to COVID-19. These forums aim to spark conversations between professionals on the frontlines of this pandemic—to facilitate the sharing of observations and insights in real time during the pandemic.
You need not be a SITC member to access and post in these discussion forums; all are encouraged to participate. Simply create a free CONNECT online account when prompted.
35th Anniversary Annual Meeting & Pre-Conference Programs
SITC Members: Register to Attend for Free!
Easily Become a SITC Member Through your SITC 2020 Registration
Share This Exciting Virtual Meeting Within Your Network:
COVID-19 Implications for Patient Management Forum
Purpose: Conversations directly relevant to patient care
Audience: Practicing clinicians and staff, clinical investigators
Suggested topics: Demographics, clinical presentation, diagnostic testing, patient management issues/insights, patterns in clinical complications, difficult cases
COVID-19 Considerations for Basic and Translational Research Forum
Purpose: Conversations directly relevant to research
Audience: Laboratory and translational scientists
Suggested topics: Data sharing, emerging literature, sample/tissue collection, model/reagent development, opportunities for collaboration, translational insights, research hypotheses
SITC has compiled resources from a variety of sources for oncology professionals to access rapidly changing information on the COVID-19 pandemic. These links, reviewed and deemed relevant by SITC, capture updates from external organizations and will be updated on a regular basis as new resources become available.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com